AC
ALLO icon

Aaron Cowen’s Allogene Therapeutics ALLO Stock Holding History

Aaron Cowen’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-265,116
Closed -$3.96M – 92
2021
Q4 		$3.96M Buy
+265,116
New +$4.68M 0.08% 75
2021
Q1 		– Sell
-483,200
Closed -$12.2M – 107
2020
Q4 		$12.2M Buy
+483,200
New +$15.7M 0.17% 56

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Aaron Cowen's ALLO Position: Q1 2022 in Review

Aaron Cowen sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 265,116 shares — an estimated $3.96M sold.

Aaron Cowen first reported a position in ALLO in Q4 2020 and held it in 2 quarters. The position peaked at $12.2M in Q4 2020. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

  • Aaron Cowen reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Aaron Cowen sold 265,116 Allogene Therapeutics shares in Q1 2022, an estimated $3.96M.
  • Aaron Cowen first reported a position in Allogene Therapeutics in Q4 2020 and held it in 2 quarters.
  • Aaron Cowen's Allogene Therapeutics position peaked at $12.2M in Q4 2020.
  • 180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Suvretta Capital Management's 13F filing for Q1 2022, filed 16 May 2022.